What are the standard first-line treatment options for Bladder Cancer

First-Line Treatment Options for Bladder Cancer

The standard first-line treatment for bladder cancer depends on the stage and type of cancer at diagnosis. Let me walk you through the main approaches:

For Non-Muscle-Invasive Bladder Cancer (Early Stage)

According to NCCN Guidelines, early-stage bladder cancers (Ta, T1, or carcinoma in situ/CIS) are typically treated with:

Transurethral Resection of the Bladder Tumor (TURBT)

• This is a minimally invasive procedure where the surgeon uses a special instrument to remove the tumor through the urethra (no external incisions)
• Often combined with an immediate intravesical instillation (medication placed directly into the bladder) of chemotherapy like mitomycin C or gemcitabine
• This local treatment helps reduce the risk of recurrence

Intravesical BCG (Bacillus Calmette-Guérin)

• A type of immunotherapy delivered directly into the bladder
• Considered the gold standard for higher-risk non-muscle-invasive disease
• Helps train the immune system to recognize and attack cancer cells

For Muscle-Invasive Bladder Cancer (Advanced Stage)

For cancers that have invaded the muscle layer of the bladder, NCCN Guidelines recommend more aggressive approaches:

Radical Cystectomy (Surgical Removal)

• Removal of the entire bladder, surrounding tissues, and lymph nodes
• Often the primary treatment for muscle-invasive disease
• May be combined with neoadjuvant chemotherapy (chemotherapy given before surgery)

Neoadjuvant Chemotherapy + Surgery

• Cisplatin-based chemotherapy given first to shrink the tumor
• Followed by radical cystectomy
• This combination improves outcomes compared to surgery alone

Bladder-Preserving Chemoradiotherapy

• For patients who want to keep their bladder or cannot tolerate surgery
• Combines chemotherapy with radiation therapy
• Requires careful patient selection and close monitoring

For Metastatic Bladder Cancer (Stage IV)

When cancer has spread beyond the bladder, NCCN Guidelines indicate systemic therapy (treatment affecting the whole body) as the primary approach:

First-Line Chemotherapy Options:

• Cisplatin-based regimens (like gemcitabine + cisplatin) - the traditional standard
• For patients who cannot receive cisplatin due to kidney function or other factors, alternative chemotherapy regimens are available

Immunotherapy (Checkpoint Inhibitors):

• Atezolizumab may be considered for cisplatin-ineligible patients, particularly if PD-L1 testing shows positive results
• These drugs help the immune system recognize and attack cancer cells
• According to NCCN Guidelines, the combination of pembrolizumab alone or with chemotherapy has been studied, though recent data showed chemotherapy alone may be more effective

Targeted Therapies:

• Erdafitinib - for patients with specific FGFR3 genetic mutations
• Fam-trastuzumab deruxtecan - for patients with HER2 overexpression
• These require molecular/genomic testing to identify if your cancer has these specific mutations

Key Point About Molecular Testing

According to NCCN Guidelines, patients with advanced bladder cancer (stages IVA and IVB) should have molecular/genomic testing performed early in their diagnosis. This testing looks for specific genetic changes that may make certain targeted therapies or immunotherapies more effective for your particular cancer.

---

Questions to Ask Your Oncologist

1. What stage is my bladder cancer, and what does that mean for my treatment options?
2. Am I a candidate for cisplatin-based chemotherapy, or do I have kidney function concerns?
3. Should I have molecular/genomic testing done, and if so, what specific mutations will you test for?
4. If surgery is recommended, can you explain the differences between bladder-preserving approaches and radical cystectomy?
5. What are the side effects I should expect from my recommended treatment, and how will we manage them?
6. Are there clinical trials available for my specific stage and type of bladder cancer?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.